| 1.44 0.07 (5.11%) | 09-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.78 | 1-year : | 2.04 |
| Resists | First : | 1.52 | Second : | 1.75 |
| Pivot price | 1.4  |
|||
| Supports | First : | 1.17 | Second : | 0.97 |
| MAs | MA(5) : | 1.37 |
MA(20) : | 1.44 |
| MA(100) : | 1.98 |
MA(250) : | 3.83 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 48.6 |
D(3) : | 45.7 |
| RSI | RSI(14): 48 |
|||
| 52-week | High : | 13.25 | Low : | 1.17 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ENVB ] has closed below upper band by 47.7%. Bollinger Bands are 81.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 49 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.43 - 1.44 | 1.44 - 1.44 |
| Low: | 1.35 - 1.36 | 1.36 - 1.37 |
| Close: | 1.4 - 1.42 | 1.42 - 1.43 |
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Fri, 28 Aug 2026
Enveric Biosciences Inc (NASDAQ: ENVB) Share Price, ENVB Stock News, ENVB Share Price & Updates - Kalkine
Thu, 20 Aug 2026
ARMISTICE CAPITAL, LLC Acquires Stake in Enveric Biosciences Inc (ENVB) - GuruFocus
Fri, 14 Aug 2026
Armistice Capital (ENVB) discloses 405,092-share position in Enveric Biosciences - Stock Titan
Fri, 14 Aug 2026
Enveric Biosciences reports $3.0M net loss, $8.3M cash on hand for Q2 2026 - TradingView
Thu, 13 Aug 2026
Enveric Biosciences (ENVB) investors disclose 2.93% stake via 111,145-share warrants - Stock Titan
Mon, 27 Jul 2026
Enveric Biosciences Inc (ENVB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 8.8 (%) |
| Held by Institutions | 12.5 (%) |
| Shares Short | 19 (K) |
| Shares Short P.Month | 16 (K) |
| EPS | -12.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.93 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -87.4 % |
| Return on Equity (ttm) | -170.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.12 |
| PEG Ratio | 0 |
| Price to Book value | 0.36 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|